Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Efpeglenatide and Clinical Outcomes with and without Concomitant Sodium-Glucose Co-Transporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O TrialCirculation 2021 Nov 14;[EPub Ahead of Print], CSP Lam, C Ramasundarahettige, KRH Branch, N Sattar, J Rosenstock, R Pratley, S Del Prato, RD Lopes, E Niemoeller, NS Khurmi, S Baek, HC Gerstein
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.